{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:46:37Z","timestamp":1780541197098,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10147-026-02958-8","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:32:28Z","timestamp":1768548748000},"page":"484-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["18F-PSMA-PET\/CT in comparison with whole-body MRI and combination of conventional CT and bone scintigraphy for detection of recurrent disease in prostate cancer patients with rising PSA levels after initial definitive treatment"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-6624","authenticated-orcid":false,"given":"Shiori","family":"Murata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaku","family":"Moribata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Himoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihito","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonao","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2958_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2958_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, Van Den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164\u2013182. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010","journal-title":"Eur Urol"},{"key":"2958_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630\u2013642. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002","journal-title":"Eur Urol"},{"key":"2958_CR4","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, De Almeida Luz M, De Giorgi U et al (2023) Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 389:1453\u20131465","journal-title":"N Engl J Med"},{"key":"2958_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.23.01157","volume":"42","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Heller G, Hillman DW et al (2024) Presto: A Phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol 42:1114\u20131123","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"2958_CR6","first-page":"S37","volume":"7","author":"RJ Kumar","year":"2005","unstructured":"Kumar RJ, Barqawi A, Crawford ED (2005) Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 7(Suppl 5):S37\u2013S43","journal-title":"Rev Urol"},{"key":"2958_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417\u2013428","journal-title":"N Engl J Med"},{"key":"2958_CR8","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","volume":"299","author":"BJ Trock","year":"2008","unstructured":"Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760\u20132769","journal-title":"JAMA"},{"key":"2958_CR9","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035\u20132041","journal-title":"J Clin Oncol"},{"key":"2958_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","volume":"55","author":"I Jambor","year":"2016","unstructured":"Jambor I, Kuisma A, Ramadan S et al (2016) Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT, 18F-NaF PET\/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 55:59\u201367. https:\/\/doi.org\/10.3109\/0284186X.2015.1027411","journal-title":"Acta Oncol"},{"key":"2958_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.033","journal-title":"Eur Urol"},{"key":"2958_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach PJ, Francis R, Emmett L et al (2018) The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 59:82\u201388. https:\/\/doi.org\/10.2967\/jnumed.117.197160","journal-title":"J Nucl Med"},{"key":"2958_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486\u2013495. https:\/\/doi.org\/10.1007\/s00259-012-2298-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2958_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid \u2076\u2078Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668\u2013674. https:\/\/doi.org\/10.2967\/jnumed.115.154153","journal-title":"J Nucl Med"},{"key":"2958_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, Van Den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263\u2013282. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046","journal-title":"Eur Urol"},{"key":"2958_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/jnumed.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Opitz M et al (2023) Unspecific 18F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med 64:738\u2013743. https:\/\/doi.org\/10.2967\/jnumed.118.215434","journal-title":"J Nucl Med"},{"key":"2958_CR17","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","volume":"48","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seide SE, Mingels C et al (2021) Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging 48:2978\u20132989. https:\/\/doi.org\/10.1007\/s00259-021-05210-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2958_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12149-021-01704-6","volume":"36","author":"T Otani","year":"2022","unstructured":"Otani T, Saga T, Ishimori T et al (2022) Detection efficacy of PET\/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Ann Nucl Med 36:302\u2013309. https:\/\/doi.org\/10.1007\/s12149-021-01704-6","journal-title":"Ann Nucl Med"},{"key":"2958_CR19","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.2967\/jnumed.116.175810","volume":"57","author":"N Harada","year":"2016","unstructured":"Harada N, Kimura H, Onoe S et al (2016) Synthesis and biologic evaluation of novel 18F-labeled probes targeting prostate-specific membrane antigen for PET of prostate cancer. J Nucl Med 57:1978\u20131984. https:\/\/doi.org\/10.2967\/jnumed.116.175810","journal-title":"J Nucl Med"},{"key":"2958_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101489","volume":"9","author":"R Aizawa","year":"2024","unstructured":"Aizawa R, Otani T, Ogata T et al (2024) Spatial pattern of intraprostatic recurrence after definitive external-beam radiation therapy for prostate cancer: implications for focal boost to intraprostatic dominant lesion. Adv Radiat Oncol 9:101489. https:\/\/doi.org\/10.1016\/j.adro.2024.101489","journal-title":"Adv Radiat Oncol"},{"key":"2958_CR21","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","volume":"48","author":"S Malaspina","year":"2021","unstructured":"Malaspina S, Anttinen M, Taimen P et al (2021) Prospective comparison of 18F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 48:2951\u20132959. https:\/\/doi.org\/10.1007\/s00259-021-05296-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2958_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2967\/jnumed.119.234906","volume":"61","author":"M Kroenke","year":"2020","unstructured":"Kroenke M, Wurzer A, Schwamborn K et al (2020) Histologically confirmed diagnostic efficacy of 18F-rhPSMA-7 PET for N-staging of patients with primary high-risk prostate cancer. J Nucl Med 61:710\u2013715. https:\/\/doi.org\/10.2967\/jnumed.119.234906","journal-title":"J Nucl Med"},{"key":"2958_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.euo.2020.06.012","volume":"4","author":"M Anttinen","year":"2021","unstructured":"Anttinen M, Ettala O, Malaspina S et al (2021) A prospective comparison of 18F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion-weighted imaging, and single-photon emission computed tomography\/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE). Eur Urol Oncol 4:635\u2013644. https:\/\/doi.org\/10.1016\/j.euo.2020.06.012","journal-title":"Eur Urol Oncol"},{"key":"2958_CR24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","volume":"46","author":"LM Sawicki","year":"2019","unstructured":"Sawicki LM, Kirchner J, Buddensieck C et al (2019) Prospective comparison of whole-body MRI and 68Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 46:1542\u20131550. https:\/\/doi.org\/10.1007\/s00259-019-04308-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2958_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2967\/jnumed.116.183483","volume":"58","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Sattler LP, Mier W et al (2017) The clinical impact of additional late PET\/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med 58:750\u2013755. https:\/\/doi.org\/10.2967\/jnumed.116.183483","journal-title":"J Nucl Med"},{"key":"2958_CR26","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.21873\/anticanres.17623","volume":"45","author":"R Aizawa","year":"2025","unstructured":"Aizawa R, Ogata T, Goto T et al (2025) Clinical outcomes of metastasis-directed therapy for oligo-metastatic prostate cancer diagnosed using PSMA-PET\/CT or whole-body MRI. Anticancer Res 45:2515\u20132525","journal-title":"Anticancer Res"},{"key":"2958_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.23736\/S0393-2249.18.03081-3","volume":"70","author":"A Eissa","year":"2018","unstructured":"Eissa A, Elsherbiny A, Coelho RF et al (2018) The role of 68Ga-PSMA PET\/CT scan in biochemical recurrence after primary treatment for prostate cancer: A systematic review of the literature. Minerva Urol Nefrol 70:462\u2013478","journal-title":"Minerva Urol Nefrol"},{"key":"2958_CR28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00330-018-5682-x","volume":"29","author":"E Dyrberg","year":"2019","unstructured":"Dyrberg E, Hendel HW, Huynh THV et al (2019) 68Ga-PSMA-PET\/CT in comparison with 18F-fluoride-PET\/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol 29:1221\u20131230. https:\/\/doi.org\/10.1007\/s00330-018-5682-x","journal-title":"Eur Radiol"},{"key":"2958_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215286","author":"J Van Damme","year":"2021","unstructured":"Van Damme J, Tombal B, Collette L et al (2021) Comparison of 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) with diffusion sequences (DWI) in the staging of advanced prostate cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers13215286","journal-title":"Cancers"},{"key":"2958_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.23736\/S0393-2249.18.03059-X","volume":"70","author":"S Albisinni","year":"2018","unstructured":"Albisinni S, Aoun F, Marcelis Q et al (2018) Innovations in imaging modalities for recurrent and metastatic prostate cancer: A systematic review. Minerva Urol Nefrol 70:347\u2013360","journal-title":"Minerva Urol Nefrol"},{"key":"2958_CR31","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D et al (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926\u2013937. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.021","journal-title":"Eur Urol"},{"key":"2958_CR32","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00330-014-3229-3","volume":"24","author":"K Beiderwellen","year":"2014","unstructured":"Beiderwellen K, Huebner M, Heusch P et al (2014) Whole-body [18F]FDG PET\/MRI vs. PET\/CT in the assessment of bone lesions in oncological patients: initial results. Eur Radiol 24:2023\u20132030. https:\/\/doi.org\/10.1007\/s00330-014-3229-3","journal-title":"Eur Radiol"},{"key":"2958_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00330-006-0361-8","volume":"17","author":"GP Schmidt","year":"2007","unstructured":"Schmidt GP, Schoenberg SO, Schmid R et al (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939\u2013949. https:\/\/doi.org\/10.1007\/s00330-006-0361-8","journal-title":"Eur Radiol"},{"key":"2958_CR34","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M et al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856\u2013863. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096","journal-title":"JAMA Oncol"},{"key":"2958_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","volume":"18","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Macura KJ, Mena E et al (2016) PSMA-based [18F] DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol 18:411\u2013419. https:\/\/doi.org\/10.1007\/s11307-016-0957-6","journal-title":"Mol Imaging Biol"},{"key":"2958_CR36","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"T Pyka","year":"2016","unstructured":"Pyka T, Okamoto S, Dahlbender M et al (2016) Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43:2114\u20132121. https:\/\/doi.org\/10.1007\/s00259-016-3435-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2958_CR37","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.116.185538","volume":"58","author":"F Dietlein","year":"2017","unstructured":"Dietlein F, Kobe C, Neubauer S et al (2017) PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med 58:947\u2013952. https:\/\/doi.org\/10.2967\/jnumed.116.185538","journal-title":"J Nucl Med"},{"key":"2958_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bju.13540","volume":"119","author":"PJ van Leeuwen","year":"2017","unstructured":"van Leeuwen PJ, Emmett L, Ho B et al (2017) Prospective evaluation of 68Gallium-PSMA PET\/CT for preoperative lymph node staging in prostate cancer. BJU Int 119:209\u2013215. https:\/\/doi.org\/10.1111\/bju.13540","journal-title":"BJU Int"},{"key":"2958_CR39","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25:7448\u20137454. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1050","journal-title":"Clin Cancer Res"},{"key":"2958_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euo.2021.02.003","volume":"4","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Hadaschik B, Hamdy FC et al (2021) Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: a systematic review. Eur Urol Oncol 4:714\u2013730. https:\/\/doi.org\/10.1016\/j.euo.2021.02.003","journal-title":"Eur Urol Oncol"},{"key":"2958_CR41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE Phase 2 randomized clinical trial. JAMA Oncol 6:650\u2013659","journal-title":"JAMA Oncol"},{"key":"2958_CR42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.clgc.2020.08.002","volume":"19","author":"R Mazzola","year":"2021","unstructured":"Mazzola R, Francolini G, Triggiani L et al (2021) Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer 19:230\u2013236. https:\/\/doi.org\/10.1016\/j.clgc.2020.08.002","journal-title":"Clin Genitourin Cancer"},{"key":"2958_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.929444","volume":"12","author":"M Alberto","year":"2022","unstructured":"Alberto M, Yim A, Papa N et al (2022) Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Front Oncol 12:929444. https:\/\/doi.org\/10.3389\/fonc.2022.929444","journal-title":"Front Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02958-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02958-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02958-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:04:38Z","timestamp":1771952678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02958-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02958-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}